Rocket Pharmaceuticals is a late-stage biotechnology company focused on the development, manufacturing, and commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need. The company utilizes a multi-platform approach to create gene therapy product candidates aimed at correcting the underlying genetic causes of complex inherited cardiomyopathies and related disorders. Its primary business segments involve the advancement of AAV and lentiviral vector-based therapies, with a strategic focus on rare cardiovascular indications such as hypertrophic, arrhythmogenic, and dilated cardiomyopathies. Key product candidates include RP-A501 for Danon disease and KRESLADI for Fabry disease, alongside programs for polycystic kidney disease. Rocket operates in-house cGMP manufacturing facilities to enable end-to-end control of clinical production and process development. The company serves patients in the United States and the European Union, with potential expansion into Asia. It holds global commercialization and development rights to its pipeline under internally developed intellectual property and royalty-bearing license agreements. Rocket collaborates with scientific experts, healthcare providers, and patient communities to address real-world needs in rare disease treatment.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage rocketpharma.com
Sector Healthcare IR page ir.rocketpharma.com
Tags
gene therapy, rare diseases, cardiovascular, aav vectors, lentiviral vectors, danon disease, fabry disease, polycystic kidney disease, cgmp manufacturing, in vivo delivery, ex vivo delivery, RP-A501, KRESLADI, LAMP2B, AAV9
Press page —

Metrics

Valuation  
Market cap $ 250.62M
Market cap (USD) $ 250.62M
P/E -15.00
PEG —
P/BV 0.77
P/S —
P/OCF -1.58
P/FCF -1.58
Dividend yield —
Turnover / mcap —
Returns  
ROE -60.3%
ROI -101.9%
ROIC -79.4%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 9.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -30.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Assets 330.449M 527.7M 566.341M 551.807M 497.02M 590.824M 372.121M 251.313M 101.778M 129.647M 113.321M 5.52M
Net profit -223.123M -258.746M -245.595M -221.863M -169.069M -139.7M -77.27M -74.518M -29.497M -42.854M -67.982M -9.531M
Free cash flow -190.454M -215.586M -211.352M -186.5M -128.783M -95.247M -87.932M -55.241M -26.182M -37.753M -17.828M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 3.51 12.57 29.97 19.57 21.83 54.84 22.76 14.82 — — — —
Price performance 12m -0.72 -0.58 0.53 -0.1 -0.6 1.41 0.54 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 0.00 2.4M 21.8M 22.6M 22.9M 25M 25.5M 24.9M
Cash and deposits (USD) 29.8M 78.7M 111M 185M 297M 233M 141M 55.9M 164M 77.6M
Intangible assets (USD) — — — — — 0.00 25.7M 25.2M 25.2M 25.2M
Right-of-use assets (USD) — — 0.00 2.05M 914,000 1.57M 1.97M 3.9M 4.17M 3.21M
Cash flow detail
Operating cash flow (USD) -37.3M -26.1M -53.8M -64.7M -74.6M -121M -178M -195M -210M -190M
Purchases of property, plant and equipment (USD) -487,000 -70,000 -1.45M -23.3M -20.6M -7.62M -8.36M -16.4M -5.86M -440,000
Change in payables (cash effect) (USD) -41,000 -1.14M 5.89M -2.72M 11M -4.83M 9.67M 10.1M 6.07M -10.4M
Share buybacks (cash effect) (USD) 0.00 0.00 -668,000 0.00 -72,000 0.00 — — — —
Interest paid (cash effect) (USD) 0.00 -2.96M -4.49M -2.99M -2.96M -148,000 0.00 0.00 — —
Income taxes paid (cash effect) (USD) 0.00 0.00 -2,000 -26,000 0.00 0.00 — — — 0.00
Share-based compensation (USD) 2.91M 4.04M 13.6M 13.4M 18.6M 29.2M 31M 39.4M 43.9M 37.1M
Free cash flow (OCF - PPE - intangibles) (USD) -37.8M -26.2M -55.2M -87.9M -95.2M -129M -187M -211M -216M -190M
Income detail
Research and development expense (USD) 32M 14.2M 53.3M 58.6M 106M 125M 166M 186M 171M 142M
↳ 5y CAGR +32.0% +58.5% +60.0% +53.3% +31.4% +63.4% +28.5% +23.9% +5.9%
Total comprehensive income (USD) -42.9M -29.5M -74.6M -77.1M -140M -169M -222M -245M -259M -223M
Comprehensive income to owners (USD) -7.57M -19.6M -74.6M -77.1M -140M -169M -222M -245M -259M -223M
Reported Mar 8, 2019 Mar 8, 2019 May 9, 2019 Mar 6, 2020 Mar 1, 2021 Feb 28, 2023 Feb 28, 2023 Feb 27, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027

October Danon disease investor webinar highlighted updated longer-term RP-A501 Phase 1 findings and encouraging initial safety observations in the first three patients treated under the modified Pivotal Phase 2 protocol

Dosing initiated in the Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy

KRESLADI™ achieved commercial readiness on October 1, 2026; Qualified Treatment Centers activated and ready to begin commercial patient onboarding

Cash, cash equivalents and investments of approximately $279.4 million as of September 30, 2026, including the initial $35 million Hercules draw, are expected to fund planned operations into Q3 2028. Additional borrowings could extend runway into 2029, subject to borrowing conditions, draw timing and amounts, and operating expenditures.

CRANBURY, NJ – November 12, 2026 – Rocket Pharmaceuticals, Inc.

Oct 15, 2026 |

PDF Version

CRANBURY, N.J.--(BUSINESS WIRE)--Oct. 15, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the company will attend Chardan’s 10th Annual Healthcare Conference. The company will participate in a panel on Tuesday, October 20, 2026, at 11:30 AM ET and host investor meetings.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket's cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company’s integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities and extensive clinical experience in cardiac gene therapy.

Oct 7, 2026 |

PDF Version

CRANBURY, N.J.--(BUSINESS WIRE)--Oct. 7, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported encouraging initial safety observations in the first three patients treated under the modified protocol.

Key highlights included:

  • Pivotal Phase 2 trial: The FDA-aligned pivotal efficacy population includes 12 male patients receiving commercial-grade RP-A501 at the recalibrated dose. The first three patients treated under the modified protocol count toward this population. Trial success requires at least seven patients to meet both response criteria at 12 months: myocardial LAMP2 protein expression of at least Grade 1 and a reduction in left ventricular mass index of at least 10% from baseline. These co-primary endpoints are intended to support a potential accelerated approval pathway.

  • Modified protocol: The first three patients treated at the recalibrated dose completed the protocol-specified initial observation period without clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome, as reported during the webinar. Follow-up is ongoing, and these initial observations are preliminary.

  • Phase 1 results: At approximately 12 months, all six patients in the principal Phase 1 analysis demonstrated myocardial LAMP2 protein expression and at least a 10% reduction in left ventricular mass index. At follow-up of approximately three to seven years, left ventricular mass index was below baseline in five of six patients, with reductions of at least 10% in four patients. All six patients also had sustained reduction of cardiac biomarkers and improvements of quality of life.

  • **Original-dose Phase 2 results:**Three of four patients with longitudinal efficacy assessments achieved at least a 10% reduction in left ventricular mass index. Safety findings from the original-dose study, including thrombotic microangiopathy and a fatal serious adverse reaction, informed the recalibrated dose, revised immunomodulation regimen and enhanced safety monitoring now in place.

  • **Patient population:**Genetic and clinical analyses converged on a modeled U.S. Danon disease population of approximately 10,000–11,000, including 4,000 males. Rocket’s initial focus is males with symptomatic hypertrophic cardiomyopathy.

  • Upcoming milestones: Rocket expects to complete pivotal trial dosing by mid-2027, with topline results anticipated mid-2028.

A replay of the webinar and the accompanying presentation are available in the Investors section of Rocket’s website at ir.rocketpharma.com.

About RP-A501

RP-A501 is Rocket’s investigational gene therapy for the treatment of Danon disease and the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies. RP-A501 has the potential to restore or stabilize cardiac function in patients with Danon disease. RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a functional version of the human LAMP2B transgene (AAV9.LAMP2B) which is administered as a single intravenous (IV) infusion. In clinical studies, RP-A501 has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which led to improved cardiac structure and function in patients. RP-A501 holds FDA RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S. along with ATMP and PRIME designations in the EU.

About Danon Disease

Danon disease is a rare X-linked inherited, multi-organ lysosomal-associated disorder with a devastating clinical course. The causative mutation has been identified in the gene encoding for lysosome-associated membrane protein, otherwise known as LAMP2, an important mediator of autophagy and primarily expressed in heart, skeletal muscle and brain tissue. This mutation results in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to heart failure, and for male patients, frequent death during adolescence or early adulthood. The only available definitive treatment option for Danon disease is cardiac transplantation, which is associated with substantial complications and is not considered curative, representing the high unmet medical need for patients with Danon disease.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket's cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company’s integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities and extensive clinical experience in cardiac gene therapy.

Prompts

Rocket Pharmaceuticals, Inc. (ticker RCKT), listed in United States.

Company History

Date Change Detail
Nov 13, 2017 Renamed INOTEK PHARMACEUTICALS CORP → ROCKET PHARMACEUTICALS, INC.
— Former tickers RCKTW

ETFs Holding Rocket Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.08% 77,033 $ 286.563K Aug 31, 2026
FSEV 0.06% 1,170 $ 4,001.40 Jun 30, 2026
FESM 0.03% 459,902 $ 1.573M Jun 30, 2026
RESM 0.01% 121 $ 413.82 Jun 30, 2026
AVSC 0.01% 129,675 $ 280.098K Nov 16, 2026
DFAS 0.00% 537,482 $ 1.285M Nov 12, 2026
DXUV 0.00% 51,048 $ 122.005K Nov 12, 2026
DFAC 0.00% 194,131 $ 463.973K Nov 12, 2026
DFAU 0.00% 20,859 $ 49.853K Nov 12, 2026
DFUS 0.00% 29,861 $ 71.368K Nov 12, 2026
DCOR 0.00% 9,894 $ 23.647K Nov 12, 2026
AVSU 0.00% 2 $ 4.32 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
RCKT canonical Common share — US nasdaq 2.25 USD 2026-11-13
RCKTW Warrant — US nasdaq — —